DDSolver: An Add-In Program for Modeling and Comparison of Drug Dissolution Profiles
Journal Title: The AAPS Journal - Year 2010, Vol 12, Issue 3
Abstract
The online version of this article (doi:10.1208/s12248-010-9185-1) contains supplementary material, which is available to authorized users.
Authors and Affiliations
Yong Zhang, Meirong Huo, Jianping Zhou, Aifeng Zou, Weize Li, Chengli Yao, Shaofei Xie
Keywords
Related Articles
- EP ID EP681385
- DOI 10.1208/s12248-010-9185-1
- Views 65
- Downloads 0
Duel-Acting Subcutaneous Microemulsion Formulation for Improved Migraine Treatment with Zolmitriptan and Diclofenac: Formulation and In Vitro-In Vivo Characterization
Subcutaneous triptan provides immediate analgesia in migraine and cluster headache but is limited by high pain recurrence due to rapid drug elimination. A dual-acting subcutaneous formulation providing immediate release...
Role of MRP4 and MRP5 in biology and chemotherapy
Nucleotide efflux (especially cyclic nucleotides) from a variety of mammalian tissues, bacteria, and lower eukaryotes has been studied for several decades. However, the molecular identity of these nucleotide efflux trans...
Development, Validation, and Clinical Implementation of an Assay to Measure Total Antibody Response to Naglazyme® (Galsulfase)
Naglazyme® (galsulfase, rhASB) was developed as enzyme replacement therapy for mucopolysaccharidosis type VI. Naglazyme generated an IgG antibody response in most patients. To better characterize Naglazyme immuno...
Patent issues in drug development: Perspectives of a pharmaceutical scientist-attorney
The major purpose of this article is to emphasize the need for pharmaceutical scientists to have a better understanding of patent fundamentals. This need is illustrated by analyses of key scientific and legal issues that...
Conformational characteristics of the interaction of SR141716A with the CB1 cannabinoid receptor as determined through the use of conformationally constrained analogs
Interest in cannabinoid pharmacology increased dramatically upon the identification of the first cannabinoid receptor (CB1) in 1998 and continues to expand as additional endocannabinoids and cannabinoid receptors are dis...